- Home
- ITRM vs DYAI Comparison
ITRM vs DYAI Comparison
Compare ITRM & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- DYAI
- Stock Information
- Founded
- ITRM 2015
- DYAI 1979
- Country
- ITRM Ireland
- DYAI United States
- Employees
- ITRM N/A
- DYAI N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITRM Health Care
- DYAI Health Care
- Exchange
- ITRM Nasdaq
- DYAI Nasdaq
- Market Cap
- ITRM 36.3M
- DYAI 31.3M
- IPO Year
- ITRM 2018
- DYAI 2004
- Fundamental
- Price
- ITRM $0.97
- DYAI $0.99
- Analyst Decision
- ITRM Strong Buy
- DYAI Strong Buy
- Analyst Count
- ITRM 2
- DYAI 1
- Target Price
- ITRM $7.00
- DYAI $6.00
- AVG Volume (30 Days)
- ITRM 515.1K
- DYAI 36.6K
- Earning Date
- ITRM 05-13-2025
- DYAI 05-14-2025
- Dividend Yield
- ITRM N/A
- DYAI N/A
- EPS Growth
- ITRM N/A
- DYAI N/A
- EPS
- ITRM N/A
- DYAI N/A
- Revenue
- ITRM N/A
- DYAI $3,554,344.00
- Revenue This Year
- ITRM N/A
- DYAI $22.56
- Revenue Next Year
- ITRM $108.39
- DYAI $30.95
- P/E Ratio
- ITRM N/A
- DYAI N/A
- Revenue Growth
- ITRM N/A
- DYAI 57.59
- 52 Week Low
- ITRM $0.81
- DYAI $0.93
- 52 Week High
- ITRM $3.02
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- ITRM 45.57
- DYAI 39.68
- Support Level
- ITRM $0.93
- DYAI $0.95
- Resistance Level
- ITRM $1.05
- DYAI $1.13
- Average True Range (ATR)
- ITRM 0.05
- DYAI 0.08
- MACD
- ITRM 0.01
- DYAI 0.00
- Stochastic Oscillator
- ITRM 50.00
- DYAI 30.00
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.